Assessment of anthracycline-induced cardiotoxicity with electrocardiography

Experimental Oncology

Volumn 31, Issue 2, 2009, Pages 115-117

  Horacek, J M ^a,b   Jakl, M ^a,b   Horackova, J ^a   Pudil, R ^a   Jebavy, L ^a,b   Maly, J ^a  

^a UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^b UNIVERSITY OF DEFENCE   (Czech Republic)

Author keywords

Anthracyclines; Cardiotoxicity; Electrocardiography; QRS voltage; QTc interval

Indexed keywords

CYTARABINE; DAUNORUBICIN; IDARUBICIN; MITOXANTRONE; ANTHRACYCLINE; ANTINEOPLASTIC AGENT;

ACUTE LEUKEMIA; ADULT; ARTICLE; ATRIOVENTRICULAR BLOCK; BRADYCARDIA; CARDIOTOXICITY; CLINICAL ARTICLE; COMPARATIVE STUDY; ECG ABNORMALITY; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; FEMALE; FOLLOW UP; HEART LEFT ANTERIOR BUNDLE BRANCH BLOCK; HEART REPOLARIZATION; HEART RIGHT BUNDLE BRANCH BLOCK; HUMAN; MALE; QRS COMPLEX; QT INTERVAL; QT PROLONGATION; SIDE EFFECT; TACHYCARDIA; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; DRUG EFFECT; ELECTROCARDIOGRAPHY; HEART; HEART ARRHYTHMIA; LEUKEMIA; MIDDLE AGED;

ADULT; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARRHYTHMIAS, CARDIAC; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FEMALE; HEART; HUMANS; LEUKEMIA; MALE; MIDDLE AGED;

EID: 68849090238     PISSN: 18129269     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Jones RL, Swanton C, Ewer MS. Anthracycline cardiotoxicity. Expert Opin Drug Saf 2006; 5: 791-809.
2. Ganz WI, Sridhar KS, Ganz SS, et al. Review of tests for monitoring doxorubicin-induced cardiomyopathy. Oncology 1996; 53: 461-470
3. Meinardi MT, van der Graaf WT, van Veldhuisen DJ, et al. Detection of anthracycline-induced cardiotoxicity. Cancer Treat Rev 1999; 25: 237-247
4. Pudil R, Horacek JM, Strasova A, et al. Monitoring of the very early changes of left ventricular diastolic function in patients with acute leukemia treated with anthracyclines. Exp Oncol 2008; 30: 160-162 (Pubitemid 351951396)
5. Jakl M, Horacek JM, Jebavy L, et al. Continuous 24-h monitoring of electrocardiogram during anthracycline-based therapy in acute leukemia. Leuk Res 2009; doi:10.1016/j. leukres.2008.12.024 (article in press).
6. Kilickap S, Barista I, Akgul E, et al. Early and late arrhythmogenic effects of doxorubicin. South Med J 2007; 100: 262-265 (Pubitemid 46673426)
7. Minow RA, Benjamin RS, Lee ET, et al. QRS voltage change with adriamycin administration. Cancer Treat Rep 1978; 62: 931-934
8. Larsen RL, Jakacki RI, Vetter VL, et al. Electrocardiographic changes and arrhythmias after cancer therapy in children and young adults. Am J Cardiol 1992; 70: 73-77
9. Schwartz CL, Hobbie WL, Truesdell S, et al. Corrected QT interval prolongation in anthracycline-treated survivors of childhood cancer. J Clin Oncol 1993; 11: 1906-1910 (Pubitemid 23304615)
10. Sarubbi B, Orditura M, Ducceschi V, et al. Ventricular repolarization indexes following anthracycline treatment. Heart Vessels 1997; 12: 262-266 (Pubitemid 28477119)
11. Ferrari S, Figus E, Cagnano R, et al. The role of corrected QT interval in the cardiologic follow-up of young patients treated with adriamycin. J Chemother 1996; 8: 232-236 (Pubitemid 26202873)
12. Bazett HC. An analysis of the time relations of electrocardiograms. Heart 1920; 7: 353-370
13. Common Terminology Criteria for Adverse Events v3.0 (CTCAE), available at http://ctep.cancer.gov/protocoldevelopment/ electronic-applications/docs/ ctcaev3.pdf (January 2009).
14. Wolbrette DL. Drugs that cause torsade de pointes and increase the risk of sudden cardiac death. Curr Cardiol Rep 2004; 6: 379-384
15. Liu BA, Juurlink DN. Drugs and the QT interval - caveat doctor. N Engl J Med 2004; 351: 1053-1056